Printer Friendly

United States : Landmark IMPROVE HF Trial Shows Evidence-Based Programs Result in Improvements in Heart Failure Patients Regardless of Race, and Improves Survival.

Medtronic, Inc. today announced new findings from the landmark IMPROVE HF (Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) trial, which showed equivalent improvements in the care of heart failure patients across all races and ethnicities when evidence-based, performance improvement interventions were applied in outpatient settings. The performance improvement interventions included clinical-decision support tools, structured improvement strategies (including patient assessment and management forms, and patient education materials) and patient chart reviews with performance feedback.

The majority of baseline differences in care among race groups studied were reduced or eliminated at 24 months, post-intervention. Funded by Medtronic and recently published in the Journal of the National Medical Association, the study is among the first to assess improvements in the use of clinical guideline-recommended heart failure therapies by race in the outpatient cardiology practice setting.

While African Americans are at greater risk for developing heart failure at an earlier age and at increased risk for disease-related complications and death, studies show that these patients are less likely to receive guideline-recommended medication and device therapies to treat their debilitating condition, said Clyde W. Yancy, M.D., co-chair of the IMPROVE HF steering committee and chief of the Division of Cardiology at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago. These new findings from the IMPROVE HF registry are provocative, as they demonstrate that physician education initiatives have the potential to help eradicate disparities in care and therefore greatly improve overall clinical outcomes for heart failure patients of all races.

Seven quality measures were analyzed in the IMPROVE HF study, including use of drug therapy (ACE inhibitors or angiotensin receptor blockers, beta-blockers, aldosterone antagonists and anticoagulants for atrial fibrillation); use of implantable device treatments such as implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) with a defibrillator or pacemaker; and heart failure patient education. Following implementation of the IMPROVE HF physician-based performance interventions, statistically significant improvements in the use of CRT device therapy, aldosterone antagonist drugs and heart failure education were observed across all race groups studied. As confirmed in this study, many physicians do not document race or ethnicity in the outpatient medical chart. However, results from IMPROVE HF demonstrate that improvements in outpatient care and overall treatment adherence were achieved regardless of whether the patient race was African American, Caucasian or undocumented.

2012 Al Bawaba (

Provided by an company
COPYRIGHT 2012 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Aug 31, 2012
Previous Article:United States : Advanced Health & Care in partnership with Medway Community Healthcare is finalist in Nursing Times Awards 2012.
Next Article:United States : ComEd s Youth Ambassador Program Employs and Educates Local Teens, Building Chicago s Next Generation of Energy Experts.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters